Daiwa Securities Group Inc. boosted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 91.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,062 shares of the medical instruments supplier’s stock after purchasing an additional 10,044 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Becton Dickinson and were worth $5,328,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. TRUE Private Wealth Advisors acquired a new position in shares of Becton Dickinson and during the 2nd quarter worth about $25,000. Allworth Financial LP grew its position in shares of Becton Dickinson and by 386.4% during the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 85 shares during the period. Northwest Investment Counselors LLC acquired a new position in shares of Becton Dickinson and during the 3rd quarter worth about $27,000. Hexavest Inc. acquired a new position in shares of Becton Dickinson and during the 2nd quarter worth about $28,000. Finally, Lipe & Dalton acquired a new position in shares of Becton Dickinson and during the 2nd quarter worth about $28,000. 84.29% of the stock is owned by hedge funds and other institutional investors.
Shares of BDX opened at $244.79 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.67 and a current ratio of 1.19. The stock has a 50 day simple moving average of $251.93 and a 200 day simple moving average of $246.89. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $264.74. The firm has a market capitalization of $66.59 billion, a PE ratio of 20.96, a P/E/G ratio of 1.62 and a beta of 1.09.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The business had revenue of $4.58 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same period in the previous year, the firm earned $2.93 EPS. Becton Dickinson and’s quarterly revenue was up 4.1% compared to the same quarter last year. Equities research analysts predict that Becton Dickinson and Co will post 12.58 EPS for the current fiscal year.
In related news, EVP Alexandre Conroy sold 9,829 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $255.06, for a total value of $2,506,984.74. Following the completion of the transaction, the executive vice president now directly owns 16,535 shares in the company, valued at approximately $4,217,417.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the transaction, the chief executive officer now owns 218,671 shares of the company’s stock, valued at $56,937,554.98. The disclosure for this sale can be found here. Insiders sold a total of 32,174 shares of company stock valued at $8,354,013 over the last quarter. 0.12% of the stock is owned by insiders.
BDX has been the subject of several analyst reports. Wells Fargo & Co decreased their target price on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Wednesday. Morgan Stanley boosted their target price on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Piper Jaffray Companies decreased their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus price target of $266.09.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: Diluted Earnings Per Share
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.